Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $14.49 in the prior trading day, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $14.2, down -2.00%. In other words, the price has decreased by -$2.00 from its previous closing price. On the day, 1.11 million shares were traded. AMLX stock price reached its highest trading level at $15.0599 during the session, while it also had its lowest trading level at $14.09.
Ratios:
Our goal is to gain a better understanding of AMLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Bedrosian Camille L sold 6,580 shares for $14.35 per share. The transaction valued at 94,418 led to the insider holds 175,756 shares of the business.
Bedrosian Camille L bought 6,580 shares of AMLX for $94,419 on Dec 01 ’25. On Sep 30 ’25, another insider, Klee Justin B., who serves as the Co-Chief Executive Officer of the company, sold 29,975 shares for $14.38 each. As a result, the insider received 430,952 and left with 3,325,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1559437824 and an Enterprise Value of 1221382912. Its current Enterprise Value per Revenue stands at -1836.666 whereas that against EBITDA is -6.33.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.32, which has changed by 1.909836 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 1.51%, while the 200-Day Moving Average is calculated to be 71.55%.
Shares Statistics:
The stock has traded on average 1.75M shares per day over the past 3-months and 1129320 shares per day over the last 10 days, according to various share statistics. A total of 109.77M shares are outstanding, with a floating share count of 91.15M. Insiders hold about 17.08% of the company’s shares, while institutions hold 94.74% stake in the company. Shares short for AMLX as of 1763078400 were 11911669 with a Short Ratio of 6.80, compared to 1760486400 on 9616175. Therefore, it implies a Short% of Shares Outstanding of 11911669 and a Short% of Float of 11.74.
Earnings Estimates
The market rating for Amylyx Pharmaceuticals Inc (AMLX) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.26 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.26 and -$1.79 for the fiscal current year, implying an average EPS of -$1.57. EPS for the following year is -$1.24, with 8.0 analysts recommending between -$0.76 and -$1.64.
